Amarin--2019's Biggest Buyout Target for Big Pharma
Amarin (AMRN US), a US-listed biotech firm, presented the full results of its "Reduce-It" (RI) clinical trial at a conference for the American...
4.7k Views
Hindustan And GSK In The Pursuit of Happiness
On December 3rd, the boards of both Hindustan Unilever (HUVR IN) ("HUL") and Glaxosmithkline Consumer Healthcare (SKB IN) ("GSKCH") approved a...
419 Views
Morningstar Management Behind the Moat 2018: Conference Highlights
Morningstar and PitchBook hosted the 10th annual Management Behind the Moat Conference in Chicago on Nov. 7 and 8, offering our institutional...
722 Views
Investment Thesis and Valuation
Key Drivers Royalty from Seebri / Ultibro and QVM149 (expected launch in FY20e) to peak at ¥ 4.86b in FY25e Majority of the potential milestones...
412 Views
Innovation to Help Maintain HIV Franchise Market Share and Weather Harsh Domestic Market Conditions
Continuous innovation at HIV Franchise to not only help defend market share…. Concerns about competition from Gilead Sciences Inc (GILD US)'s,...
119 Views